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Abstract
Background: Many elderly men with high-risk nonmetastatic prostate cancer
(HRnMPCa) do not receive radical treatment, despite the high mortality associated with
conservative management.
Objective: To investigate how age and comorbidity affect treatment of men with
HRnMPCa.
Design, setting, and participants: This was an observational nationwide register study
during 2001–2012.We identiﬁed 19 190men of<80 yr of age diagnosedwith HRnMPCa
in the National Prostate Cancer Register of Sweden and 95 948 age-matched men
without prostate cancer in the register of the total population.
Outcome measurements and statistical analysis: The outcome was the proportion of
men with HRnMPCa receiving radical treatment (radical prostatectomy or radiotherapy).
Vital status and the Charlson comorbidity index (CCI) were obtained from nationwide
registers. The 10-yr survival of men without prostate cancer, stratiﬁed by age and CCI,
was used as a measure of the life expectancy of the men with prostate cancer.
Results and limitations: The proportions receiving radical treatment varied with life
expectancy among men younger than 70 yr, whereas use of these treatments did not
match the long life expectancy of men in their seventies with CCI 0–1. Only 10% of men
aged 75–80 yr with CCI 0 received radical treatment despite 52% probability of 10-yr life
expectancy, compared with approximately half of the men younger than 70 yr with a
similar life expectancy. The use of radical treatment for HRnMPCa increasedwith time in
all Swedish counties, but a threefold difference between counties remained in 2009–
2012 for patients aged 70–80 yr with CCI 0-1. Uncertain external validity is a study
limitation, and the impact of physician versus patient preferences on treatment selec-
tion could not be assessed.
Conclusions: Otherwise healthy men in their seventies with HRnMPCa were less likely
to receive radical treatment than younger men with a similar life expectancy, although
increasing use of radical treatment was observed during the study period. Our ﬁndings
highlight the need for improved methods for clinical decision-making, including
improved assessment of life expectancy.
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1. Introduction
Radical prostatectomy and radiotherapy are commonly
used in elderly menwith low- or intermediate-risk prostate
cancer [1–6] despite high-level evidence of the absence of a
survival benefit within 10 yr [7–10]. Therefore, it is difficult
to understand why so many men in their seventies with
high-risk nonmetastatic prostate cancer do not receive
treatment with curative intent [2,5,6,11]. Two randomised
studies showed a survival benefit from radiotherapy in
combination with androgen deprivation therapy for men
with high-risk prostate cancer [12,13], with a similar effect
for men younger and older than 67 yr [12]. The survival
benefit is apparent within 6–8 yr after treatment
[12,13]. Without curative treatment, the 10-yr cancer-
specific mortality from high-risk prostate cancer is approx-
imately 30%, including inmen older than 75 yr at the time of
their diagnosis [14].
It is possible that the results from the SPCG-4 study have
contributed to the low use of treatment with curative intent
among older men with high-risk prostate cancer [8,9]. Sub-
group analysis in the first reports from the SPCG-4 study
indicated that the positive treatment effect of radical
prostatectomy was confined to men younger than 65 yr
[8,9]. However, most men in the SPCG-4 study had
intermediate-risk disease. Men with poorly differentiated
or locally advanced prostate cancer were excluded, and the
results from SPCG-4 can therefore not be used to guide
treatment of men with high-risk disease [8]. Furthermore,
in the final analysis of the SPCG-4 study, radical prostatec-
tomy was associated with significantly lower risks of
metastasis and androgen deprivation therapy for men older
than 65 yr [10].
The number of elderly men affected by prostate cancer is
rapidly increasing around the world [15,16], so optimisa-
tion of their treatment is essential. The International Society
of Geriatric Oncology recently expressed concerns about
undertreatment of healthy elderly men with high-risk
prostate cancer [17]. They pointed out that individual
health status rather than chronological age should guide
treatment decisions [17].
One possible reason for the undertreatment of elderly
cancer patients is that their life expectancy is under-
estimated [6,18]. The aim of the present study was to
investigate how treatment decisions for men with high-risk
nonmetastatic prostate cancer are influenced by age and
comorbidity, and to determine whether the use of radical
prostatectomy and radiotherapy is in accordance with
patients’ life expectancy.
2. Patients and methods
The Prostate Cancer Data Base Sweden (PCBaSe) 3.0 was created through
record linkages between the National Prostate Cancer Register (NPCR) of
Sweden and several other population-based, nationwide health care
registers and demographic databases. The database has previously been
described in detail [19]. The capture rate of the NPCR is 98% compared to
the Swedish Cancer Register, to which registration is mandated by law
[20]. Demographic data for men in PCBaSe Sweden were obtained from
the register of the total population. Information on underlying and
contributing causes and on the date of death was obtained from the
cause of death register, which captures all deaths in Sweden. The quality
and completeness of the Swedish national registers and databases are
high, and notiﬁcations are regularly reviewed by Statistics Sweden. The
overall agreement between the cause of death register and reviewed
medical records is approximately 86% (95% conﬁdence interval [CI]
85–87%) [21].
High-risk nonmetastatic prostate cancer was deﬁned as prostate
cancer with no evidence of metastasis (N0 or Nx, M0 or Mx) and at least
one of the following three criteria: Gleason score 8–10, local clinical
stage T3, or prostate-speciﬁc antigen (PSA) 20–49 ng/ml. The upper PSA
limit was chosen because the Swedish guidelines did not recommend
radical treatment in men with PSA 50 ng/ml during the time period
studied. PCBaSe does not include information on subcategories T2a, T2b,
and T2c for local clinical stage. Only 12 men registered in the NPCR aged
>80 yr at the time of diagnosis were treated with radical prostatectomy
or radiotherapy.We therefore restricted the analysis tomen aged<80 yr.
The study included men diagnosed between January 1, 2001 and
December 31, 2012.
For each prostate cancer case in PCBaSe, we identiﬁed ﬁvemen in the
Swedish register of the total population who matched the cases for date
of birth (1 yr) and county of residence, but who were not diagnosed with
prostate cancer. A total of 95 948 men without prostate cancer were
identiﬁed and included in PCBaSe. Of these, 3608 were subsequently
diagnosed with prostate cancer during follow-up. These latter men were
censored at the time of diagnosis and were included in the life expectancy
estimates only before the date of their prostate cancer diagnosis. All men
were followed until death, emigration, or to December 31, 2012, whichever
occurred ﬁrst.
For each man in PCBaSe, a Charlson comorbidity index (CCI) on the
date of diagnosis was constructed by grouping International Classiﬁca-
tion of Diseases (ICD) codes in the discharge diagnoses in the inpatient
register, as previously described [22,23]. The prostate cancer diagnosis
was not included in the CCI. The term healthy men is used for men with
no registered comorbidity (CCI 0).
Differences among the 21 counties of Sweden and temporal trends in
the use of radical prostatectomy and radiotherapy were also analysed.
Radiotherapy was recommended in the Swedish guidelines as the
Patient summary: We performed a nationwide register study that showed that many
healthy men in their seventies live for at least another 10 yr. Despite this long life
expectancy, men in their seventies with high-risk nonmetastatic prostate cancer were
often not treated with radical prostatectomy or radiotherapy, possibly because their
life expectancy was underestimated. Our study highlights the need for improved
clinical decision-making, which should incorporate an assessment of the patient’s life
expectancy.
# 2014 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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treatment of choice for locally advanced prostate cancer (local stage T3),
whereas radical prostatectomy and radiotherapy were both recom-
mended options for localised disease. Radical prostatectomy was
performed in all counties and radiotherapy was available in most
counties.
2.1. Statistical analysis
Cumulative survival probabilities for the men without prostate cancer,
stratiﬁed by age and comorbidity, were analysed using the Kaplan-Meier
method, and 95% CIs were calculated. We assumed that the 10-yr
survival probability would be equivalent to the 10-yr survival for men
with prostate cancer at the same age and with the same CCI, if cured of
their prostate cancer. The 10-yr survival probability for men without
prostate cancer was then used as ameasure of the life expectancy for the
men with prostate cancer. Two-sided 95% CIs for proportions of men
receiving radical prostatectomy or radiotherapy were calculated using
the Wilson score method [24]. The statistical analysis was performed
with R, version 3.0.1 (R Foundation for Statistical Computing, Vienna,
Austria).
3. Results
We identified 19 190 men aged <80 yr with high-risk
nonmetastatic prostate cancer diagnosed between 2001 and
2012, and 95 948 age-matched men from the general
population without prostate cancer (Table 1). The propor-
tions of men with prostate cancer younger than 70 yr who
received radical prostatectomy or radiotherapy varied
togetherwith the 10-yr survival probability formenwithout
prostate cancer, but did not for men with prostate cancer
aged70–80 yr (Fig. 1 andTable 2). For example, despite a 52%
probability of 10-yr survival (95% CI 51–52%) for men aged
75–80 yr with CCI 0, only 10% (95% CI 9–11%) of these men
withhigh-riskprostate cancer hada radical prostatectomyor
radiotherapy, compared with 52% (95% CI 41–63%) of men
aged <65 yr with CCI 3, who had a similar 10-yr survival
[(Fig._1)TD$FIG]
Fig. 1 – The 10-yr survival probability for men in the general population without prostate cancer and the proportion of men with high-risk
nonmetastatic prostate cancer treated with radical prostatectomy or radiotherapy, stratified by age and Charlson comorbidity index (CCI). Men
without prostate cancer were matched to the men with prostate cancer for date of birth (W1 yr) and county of residence. The survival of men without
prostate cancer was counted from the date of diagnosis for the corresponding cases. The data are listed in Table 2.
Table 1 – Characteristics of men younger than 80 yr diagnosed
with high-risk nonmetastatic prostate cancer and of men without
prostate cancer matched to the prostate cancer cases for date of
birth (W1 yr) in the Prostate Cancer Database Sweden
Men with
prostate
cancer, n (%)
Men without
prostate
cancer, n (%)
Total number of men 19 190 (100) 95 948 (100)
Year of diagnosis
2001–2003 4627 (24.1) 23 134 (24.1)
2004–2006 5167 (26.9) 25 835 (26.9)
2007–2009 4778 (24.9) 23 890 (24.9)
2010–2012 4618 (24.1) 23 089 (24.1)
Age
<65 yr 4483 (23.4) 22 383 (23.3)
65–69 yr 4262 (22.2) 21 349 (22.3)
70–74 yr 4957 (25.8) 24 915 (26.0)
75–79 yr 5488 (28.6) 27 301 (28.5)
Charlson comorbidity index (CCI)
CCI 0 14 261 (74.3) 70 387 (73.4)
CCI 1 2677 (13.9) 13 174 (13.7)
CCI 2 1404 (7.3) 7231 (7.5)
CCI  3 848 (4.4) 5156 (5.4)
Prostate cancer category
Localised, high risk a 10 992 (57) –
Locally advanced b 8198 (43) –
Primary treatment
Noncurative treatment c 9614 (50.1) –
Radical prostatectomy 3236 (16.9) –
Radiotherapy 5522 (28.8) –
Other treatment with
curative intent
166 (0.9) –
No primary treatment
registered
652 (3.4) –
a T1–2 and Gleason score 8–10 and/or prostate-specific antigen (PSA)
20–49 ng/ml.
b T3, any Gleason score, PSA 49 ng/ml.
c Watchful waiting, gonadotropin-releasing hormone analogue,
orchidectomy, antiandrogen therapy, or other treatment.
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probability (46%, 95% CI 43–48%). For men without prostate
cancer aged 70–74 yr with CCI 0, the 10-yr survival
probability (70%, 95% CI 70–70%) was similar to that for
men younger than 65 yr with CCI 2 (68%, 95% CI 67–70%).
However, otherwise healthy men aged 70–74 yr with high-
risk prostate cancer were much less likely to receive radical
prostatectomy or radiotherapy (44%, 95% CI 43–46%) than
men younger than 65 years with CCI 2 (72%, 95% CI 65–78%).
The proportion of men with high-risk prostate cancer
receiving radical prostatectomy or radiotherapy increased
during the study period from 38% in 2001–2004 to 44% in
2005–2008 and 58% in 2009–2012 (Fig. 2). The increase was
greater among men aged 70–79 yr (from 15% in 2001–2004
to 38% in 2009–2012) than for those younger than 70 yr
(from 69% in 2001–2004 to 80% in 2009–2012). Although
increasing use of radical prostatectomy and radiotherapy
was observed in all 21 counties and the differences among
counties decreased, use still varied in the last time period
(2009–2012) from 47% in the county with the lowest use
to 83% in the county with the highest use. For men aged
70–80 yr with CCI 0–1, variation from 25% to 77% between
counties remained during 2009–2012. The proportion
receiving radiotherapywas not associatedwith the distance
to a radiation oncology department.
4. Discussion
Otherwise healthy Swedish men in their seventies with
high-risk nonmetastatic prostate cancer were significantly
less likely to receive radical prostatectomy or radiotherapy
than younger men with similar life expectancy. This
disparity suggests that the life expectancy of healthy
elderly men was commonly underestimated.
Table 2 – Proportion of 19 190 men with high-risk nonmetastatic
prostate cancer treated with radical prostatectomy or
radiotherapy, and 10-yr survival probability for 95 948 men in the
general population without prostate cancer, stratified by age and
comorbidity a
Men with
prostate
cancer (n)
Men with
prostate cancer
receiving RP
or RT, % (95% CI)
10-yr survival
of men without
prostate cancer,
% (95% CI)
Age <65 yr
CCI 0 3817 82 (80–83) 91 (91–91)
CCI 1 389 76 (71–80) 79 (79–80)
CCI 2 191 72 (65–78) 68 (67–70)
CCI 3 86 52 (41–63) 46 (43–48)
Age 65–69 yr
CCI 0 3322 70 (69–72) 82 (82–82)
CCI 1 552 57 (53–61) 66 (66–67)
CCI 2 255 61 (54–67) 59 (56–60)
CCI 3 133 41 (32–49) 36 (33–38)
Age 70–74 yr
CCI 0 3547 44 (43–46) 70 (70–70)
CCI 1 736 36 (32–39) 52 (51–53)
CCI 2 437 28 (24–33) 42 (41–44)
CCI 3 237 23 (18–29) 24 (23–25)
Age 75–79 yr
CCI 0 3575 10 (9–11) 52 (51–52)
CCI 1 1000 6 (5–8) 33 (32–34)
CCI 2 521 3 (4–9) 28 (27–29)
CCI 3 392 5 (3–8) 15 (14–16)
CCI = Charlson comorbidity index; CI = conﬁdence interval; RP = radical
prostatectomy; RT = radiotherapy.
a Men without prostate cancer were matched to the men with prostate
cancer for date of birth (1 yr) and county of residence. Survival of the men
without prostate cancer was counted from the date of diagnosis for the
corresponding cases diagnosis. The number of men without prostate cancer
was ﬁve times the number of men with prostate cancer in each group. The
data are also illustrated in Figure 1.
[(Fig._2)TD$FIG]
Fig. 2 – Time trends for the use of radical prostatectomy (RP) and radiotherapy (RT) in men with high-risk nonmetastatic prostate cancer in Sweden
during 2001–2012. CCI = Charlson comorbidity index; dx = diagnosis.
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Our findings add to the concerns about undertreatment
of healthy elderly men with high-risk prostate cancer
expressed by The International Society of Geriatric Oncolo-
gy [17]. As the society pointed out, men with prostate
cancer should be managed according to their individual
health status rather than their age. Our study revealed that
the opposite appears to occur frequently. The low use of
radical prostatectomy and radiotherapy observed for men
in their seventies is in accordance with a US study showing
that men older than 75 yr with high-risk nonmetastatic
prostate cancer are those most often undertreated in
comparison to the National Comprehensive Cancer Net-
work treatment guidelines [6], and with a report from
Ireland on the relation between age and treatment for
localised prostate cancer [5].
During the first years of the time period studied,
evidence was still scarce on benefits of radical treatment
in elderly men with high-risk nonmetastatic prostate
cancer. The first randomised clinical trial showing that a
combination of radiotherapy and hormonal therapy
improves survival for this group of patients was published
in 2009 [12]. The combined treatment resulted in a 10%
absolute reduction and a 32% relative reduction in overall
10-yr mortality, with a similar effect in men younger and
men older than 67 yr [12]. Another randomised study
published in 2011 confirmed these results [13]. A recent
register study indicated that radical treatment of high-risk
prostate cancer is associated with reduced mortality, even
in men older than 65 yr with comorbidities [1]. The results
from the two randomised studies probably contributed to
the increased use of radical prostatectomy and radiotherapy
in the last time period in our study.
Although the use of radical prostatectomy and radiother-
apy increased in all 21 Swedish counties, considerable
variations among counties remained throughout the study
period. The variationwasup to threefold for thegroupofmen
aged 70–80 yearswith CCI 0 or 1 during the last study period
(2009–2012). We believe that these large geographic
differences reflect variations in physician practice patterns.
A systematic review of treatment decisions for men with
localised prostate cancer suggests that variations in treat-
ment decisions are more indicative of differences in the
information provided to patients than of differences in
patient preferences [25]. Multidisciplinary conferences
reduce the impact of the views of individual physicians
[26], and are therefore recommended by Europa Uomo,
the European organisation for prostate cancer patients
[27]. However, whether the potential benefits of radical
prostatectomy or radiotherapy outweigh the risks of side
effects is a decision that only the patient himself can make.
Consensus is building on the importance of shared clinical
decision-making, with an emphasis on assessment of the
patient’s personal preferences and values [28]. Our study
suggests that toomuchweight is put on chronological age in
clinical decisions and that better assessment of life expec-
tancy is needed to improve the outcome for men with high-
risk prostate cancer.
Strengths of our study include the nationwide and
population-based design with a large sample size. One
limitation is that we did not know the proportion of men
who were recommended radical prostatectomy or radio-
therapy, but chose not to be treated. Another limitation is
that we assessed comorbidity by CCI based on discharge
diagnoses in the inpatient register, which may have led to
underestimation of comorbidity. Furthermore, our study
included men classified as having Mx disease, some of
whomwould likely have had distant metastases detected if
a staging investigation had been performed. However, we
felt it appropriate to include thesemen sincewithholding of
staging procedures (thereby categorising the disease stage
as Mx) may represent the first step towards inappropriate
withholding of a potentially curative treatment. In addition,
the 10-yr survival probabilities for Swedish men without
prostate cancer are not directly applicable to populations
with a short median lifespan, as the 80-yr median lifespan
of Swedish men is among the longest in the world. Finally,
the treatment patterns for high-risk prostate cancer may be
different in other countries, but similar concerns regarding
undertreatment of elderly men have been raised on both
sides of the Atlantic [5,6].
5. Conclusions
Our nationwide population-based study of men with high-
risk nonmetastatic prostate cancer revealed lower use of
radical prostatectomy and radiotherapy among otherwise
healthy men in their seventies than among younger men
with a similar life expectancy, suggesting that treatment
decisions relied more on chronological age than on life
expectancy. Although increasing use of radical treatments
was observed during the study period, many elderly men
with high-risk prostate cancer are probably still under-
treated. The large geographic differences in the use of
radical prostatectomy and radiotherapy, with persistent
low use in many counties, highlight the need for improved
methods for clinical decision-making, including improved
assessment of patients’ life expectancy.
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